Affiliation: GlaxoSmithKline Biologicals
- Burden of rotavirus disease in European Union countriesMontse Soriano-Gabarro
GlaxoSmithKline Biologicals, Rixensart, Belgium
Pediatr Infect Dis J 25:S7-S11. 2006..With the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine-preventable disease among children in the EU...
- Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003Montse Soriano-Gabarro
GlaxoSmithKline GSK Biologicals, Rue Institut 89, Rixensart, Belgium
Vaccine 25:A92-6. 2007..The vaccine was highly effective against the epidemic. Since 2003, the trivalent vaccine continues to be effectively used in Africa for the control of meningococcal disease epidemics...
- Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of ageJohannes Forster
MSc, 89 Rue de l Institut, 1330 Rixensart, Belgium
Pediatrics 123:e393-400. 2009..Data on the burden of rotavirus gastroenteritis are needed to guide recommendations for rotavirus vaccine use. This study was undertaken to estimate the burden of rotavirus gastroenteritis in European children <5 years of age...